IPC Signs Pharmacovigilance Partnerships with Three State Pharmacy Councils

In a major step toward strengthening India’s medicine safety ecosystem and promoting evidence-based healthcare practices, the Indian Pharmacopoeia Commission (IPC) has signed strategic Memoranda of Understanding (MoUs) with the State Pharmacy Councils of Bihar, Maharashtra and Mizoram to expand pharmacovigilance systems, improve rational medicine use and enhance patient safety across the country.

The agreements were signed at IPC headquarters in Ghaziabad by Dr. V. Kalaiselvan, Secretary-cum-Scientific Director of IPC, with representatives from the three State Pharmacy Councils in the presence of senior healthcare and policy officials.

The collaboration marks a significant expansion of India’s efforts to build a stronger nationwide medicine surveillance network amid growing focus on drug safety, adverse drug reaction monitoring and responsible pharmaceutical practices.

Strategic Collaboration to Strengthen India’s Drug Safety Infrastructure

The MoUs were signed with:

• Bihar State Pharmacy Council

• Maharashtra State Pharmacy Council

• Mizoram State Pharmacy Council

The agreements aim to establish closer institutional coordination between the Indian Pharmacopoeia Commission and state-level pharmacy regulators to strengthen healthcare systems through improved pharmacovigilance and professional training.

The signatories included:

• Dr. Prakash Sinha, President, Bihar State Pharmacy Council

• Dr. H. Lalhlenmawia, Vice-President, Mizoram State Pharmacy Council

• Mr. Atul Ahire, President, Maharashtra State Pharmacy Council

The event was attended by senior officials and healthcare representatives from participating organisations.

Focus on Rational Use of Medicines and Patient Safety

A central objective of the collaboration is to promote the rational and evidence-based use of medicines among pharmacists and healthcare institutions.

Under the agreements, the participating organisations will work toward wider dissemination and adoption of the National Formulary of India (NFI) among registered pharmacists.

The National Formulary of India serves as an important scientific reference document providing guidance on:

• Safe medicine use

• Standard treatment practices

• Rational prescribing

• Evidence-based pharmacotherapy

• Drug safety standards

Officials said efforts will also be made to establish the NFI as a mandatory reference document in hospital pharmacies across healthcare facilities in participating states.

Healthcare experts say rational medicine use is increasingly critical in addressing:

• Medication errors

• Antibiotic misuse

• Drug resistance

• Adverse drug reactions

• Polypharmacy risks

Pharmacovigilance Programme of India to Receive Major Boost

The collaboration is also expected to significantly strengthen the Pharmacovigilance Programme of India (PvPI), the country’s national drug safety monitoring system.

The MoUs focus on enhancing:

• Adverse Drug Reaction (ADR) reporting

• Pharmacovigilance awareness

• Medicine safety surveillance

• Coordination between pharmacists and healthcare institutions

As part of the initiative, the partners will support the establishment and strengthening of ADR Monitoring Centres (AMCs) in coordination with the Pharmacovigilance Programme of India.

Officials believe expanded ADR reporting networks can substantially improve India’s ability to detect, assess and respond to medicine-related safety concerns more rapidly.

Pharmacists to Receive Expanded Professional Training

The agreements also include plans for extensive professional development programmes aimed at improving pharmacist competencies and strengthening healthcare delivery systems.

IPC and the State Pharmacy Councils will jointly organise:

• Training programmes

• Workshops

• Continuing education initiatives

• Professional competency development sessions

These programmes will focus on:

• Rational medicine use

• Pharmacovigilance practices

• Pharmacopoeial standards

• Drug safety monitoring

• Patient counselling

• Regulatory compliance

Healthcare analysts say pharmacists are increasingly becoming frontline healthcare professionals in medicine safety, particularly in areas such as medication counselling, adverse reaction detection and responsible drug dispensing.

Research and Regulatory Cooperation to Expand

The partnership framework also includes cooperation in research and professional collaboration relating to:

• Drug safety

• Regulatory standards

• Rational pharmacotherapy

• Medicine quality standards

• Public health surveillance

The Indian Pharmacopoeia Commission is expected to provide:

• Technical guidance

• Scientific expertise

• Regulatory support

• Domain knowledge

while State Pharmacy Councils will facilitate coordination with:

• Pharmacists

• Hospitals

• Healthcare institutions

• Medical professionals

for implementation of various initiatives.

Public Awareness Campaigns Planned on Medicine Safety

Another major component of the collaboration involves strengthening public and professional awareness regarding medicine safety and pharmacovigilance.

The MoUs envisage targeted outreach programmes focused on:

• Safe medicine practices

• Adverse drug reaction awareness

• Pharmacopoeial standards

• Patient safety education

• Responsible medicine use

Public health experts note that improving awareness among both healthcare professionals and patients is critical for early identification of medicine-related risks and reducing preventable adverse events.

India Expanding Focus on Medicine Safety and Pharmacovigilance

India has increasingly strengthened its pharmacovigilance systems over the last decade as the country’s pharmaceutical sector continues to expand globally.

The Pharmacovigilance Programme of India plays a central role in monitoring medicine safety across the country by collecting and analysing reports of adverse drug reactions from healthcare professionals and institutions.

Strengthening pharmacovigilance has become especially important in recent years due to:

• Expanding pharmaceutical usage

• Growth in chronic disease treatment

• Increasing biologics and complex therapies

• Rising concerns over antimicrobial resistance

• Greater public awareness around medicine safety

Healthcare authorities say robust pharmacovigilance systems are essential for protecting patient safety and maintaining confidence in healthcare systems.

Senior Healthcare Leaders Attend Event

The signing ceremony was also attended by several prominent healthcare and policy experts, including:

• Dr. V. K. Paul, Former Member, NITI Aayog

• Dr. G. N. Singh, Advisor to the Chief Minister of Uttar Pradesh

• Prof. Y. K. Gupta, President, AIIMS Kalyani

Their presence reflected the broader national importance attached to strengthening medicine safety systems and healthcare quality standards.

Collaboration Seen as Step Toward Safer Healthcare Ecosystem

Officials described the agreements as part of a shared commitment to building stronger healthcare systems through enhanced pharmacovigilance, professional capacity building and evidence-based medicine practices.

Experts believe such partnerships can significantly improve coordination between regulatory agencies, pharmacists and healthcare institutions while promoting safer and more effective use of medicines nationwide.

As India continues to modernise its healthcare infrastructure and expand pharmaceutical access, strengthening medicine safety surveillance and rational drug use is increasingly viewed as a critical pillar of public health policy.